Advertisement

Topics

Anika Therapeutics, Inc.       Company Profile

06:22 EDT 25th June 2018 | BioPortfolio

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.


News Articles [815 Associated News Articles listed on BioPortfolio]

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earn...

Anika Therapeutics’ Sherwood Retires as CEO, Darling Named Successor

Charles Sherwood, CEO of Anika Therapeutics (NASDAQ: ANIK), is retiring from the company and its board of directors after nearly 20 years. Joseph Darling, Anika’s president, will succeed Sherwood as...

Anika Therapeutics (ANIK) Rating Increased to Buy at BidaskClub

Several other research analysts have also commented on ANIK. Sidoti began coverage on shares of Anika Therapeutics in a report on Friday.

Anika Craters Following Failure of Phase III Knee Osteoarthritis Study

Shares of Bedford, Mass.-based Anika Therapeutics have plunged more than 20 percent in premarket trading.

Anika Therapeutics (ANIK) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Anika Therapeutics issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.41 by , Zacks r...

Investor Network: Anika Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Anika Therapeutics, Inc. (NASDAQ: ANIK) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 9:00 ...

Anika hit by trial failure

US group Anika Therapeutics has been hit by the failure of its viscosupplement Cingal to hit targets in a Phase III trial comparing its effectiveness to a standard treatment in patients with osteoarth...

Anika reports negative top-line results from 16-02 trial of Cingal

Anika Therapeutics has reported negative top-line data in the 16-02 trial, a Phase III clinical study evaluating Cingal to treat...Read More... The post Anika reports negative top-line results from 16...

PubMed Articles [432 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1237 Associated Companies listed on BioPortfolio]

Anika Therapeutics, Inc.      

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the live...

Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing, repair and regenera...

Anika Therapeutics Incorporated

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to repair, protect and heal bone, cartilage and soft tissues. These products are currently ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Anika Therapeutics, Inc.      " on BioPortfolio

We have published hundreds of Anika Therapeutics, Inc.       news stories on BioPortfolio along with dozens of Anika Therapeutics, Inc.       Clinical Trials and PubMed Articles about Anika Therapeutics, Inc.       for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Anika Therapeutics, Inc.       Companies in our database. You can also find out about relevant Anika Therapeutics, Inc.       Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...

Palliative Care
Palliative care is the active holistic care of patients with advanced progressive illness. Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount. The goal of palliative care is achievement of the ...


Corporate Database Quicklinks



Searches Linking to this Company Record